Cargando…

Population Pharmacokinetic Analysis of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Healthy Subjects, Subjects with Various Degrees of Renal Function, and Patients with Complicated Urinary Tract Infection or Acute Uncomplicated Pyelonephritis

Cefiderocol, a novel parenteral siderophore cephalosporin, exhibits potent efficacy against most Gram-negative bacteria, including carbapenem-resistant strains. The aim of this study was to perform a population pharmacokinetic (PK) analysis based on plasma cefiderocol concentrations in healthy subje...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawaguchi, Nao, Katsube, Takayuki, Echols, Roger, Wajima, Toshihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5786804/
https://www.ncbi.nlm.nih.gov/pubmed/29038272
http://dx.doi.org/10.1128/AAC.01391-17
_version_ 1783295829341110272
author Kawaguchi, Nao
Katsube, Takayuki
Echols, Roger
Wajima, Toshihiro
author_facet Kawaguchi, Nao
Katsube, Takayuki
Echols, Roger
Wajima, Toshihiro
author_sort Kawaguchi, Nao
collection PubMed
description Cefiderocol, a novel parenteral siderophore cephalosporin, exhibits potent efficacy against most Gram-negative bacteria, including carbapenem-resistant strains. The aim of this study was to perform a population pharmacokinetic (PK) analysis based on plasma cefiderocol concentrations in healthy subjects, subjects with various degrees of renal function, and patients with complicated urinary tract infection (cUTI) or acute uncomplicated pyelonephritis (AUP) caused by Gram-negative pathogens and to calculate the fraction of the time during the dosing interval where the free drug concentration in plasma exceeds the MIC (fT(MIC)). Population PK models were developed with three renal function markers, body surface area-adjusted estimated glomerular filtration rate (eGFR), absolute eGFR, and creatinine clearance, on the basis of 2,571 plasma concentrations from 91 subjects without infection and 238 patients with infection. The population PK models with each renal function marker adequately described the plasma cefiderocol concentrations. Clear relationships of total clearance (CL) to all renal function markers were observed. Body weight and disease status (with or without infection) were also significant covariates. The CL in patients with infection was 26% higher than that in subjects without infection. The fT(MIC) values were more than 75% in all patients (and were 100% in most patients), suggesting that a sufficient exposure to cefiderocol was provided by the tested dose regimens (2 g every 8 h as the standard dose regimen) for the treatment of cUTI or AUP caused by Gram-negative pathogens.
format Online
Article
Text
id pubmed-5786804
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-57868042018-02-07 Population Pharmacokinetic Analysis of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Healthy Subjects, Subjects with Various Degrees of Renal Function, and Patients with Complicated Urinary Tract Infection or Acute Uncomplicated Pyelonephritis Kawaguchi, Nao Katsube, Takayuki Echols, Roger Wajima, Toshihiro Antimicrob Agents Chemother Pharmacology Cefiderocol, a novel parenteral siderophore cephalosporin, exhibits potent efficacy against most Gram-negative bacteria, including carbapenem-resistant strains. The aim of this study was to perform a population pharmacokinetic (PK) analysis based on plasma cefiderocol concentrations in healthy subjects, subjects with various degrees of renal function, and patients with complicated urinary tract infection (cUTI) or acute uncomplicated pyelonephritis (AUP) caused by Gram-negative pathogens and to calculate the fraction of the time during the dosing interval where the free drug concentration in plasma exceeds the MIC (fT(MIC)). Population PK models were developed with three renal function markers, body surface area-adjusted estimated glomerular filtration rate (eGFR), absolute eGFR, and creatinine clearance, on the basis of 2,571 plasma concentrations from 91 subjects without infection and 238 patients with infection. The population PK models with each renal function marker adequately described the plasma cefiderocol concentrations. Clear relationships of total clearance (CL) to all renal function markers were observed. Body weight and disease status (with or without infection) were also significant covariates. The CL in patients with infection was 26% higher than that in subjects without infection. The fT(MIC) values were more than 75% in all patients (and were 100% in most patients), suggesting that a sufficient exposure to cefiderocol was provided by the tested dose regimens (2 g every 8 h as the standard dose regimen) for the treatment of cUTI or AUP caused by Gram-negative pathogens. American Society for Microbiology 2018-01-25 /pmc/articles/PMC5786804/ /pubmed/29038272 http://dx.doi.org/10.1128/AAC.01391-17 Text en Copyright © 2018 Kawaguchi et al. https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Pharmacology
Kawaguchi, Nao
Katsube, Takayuki
Echols, Roger
Wajima, Toshihiro
Population Pharmacokinetic Analysis of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Healthy Subjects, Subjects with Various Degrees of Renal Function, and Patients with Complicated Urinary Tract Infection or Acute Uncomplicated Pyelonephritis
title Population Pharmacokinetic Analysis of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Healthy Subjects, Subjects with Various Degrees of Renal Function, and Patients with Complicated Urinary Tract Infection or Acute Uncomplicated Pyelonephritis
title_full Population Pharmacokinetic Analysis of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Healthy Subjects, Subjects with Various Degrees of Renal Function, and Patients with Complicated Urinary Tract Infection or Acute Uncomplicated Pyelonephritis
title_fullStr Population Pharmacokinetic Analysis of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Healthy Subjects, Subjects with Various Degrees of Renal Function, and Patients with Complicated Urinary Tract Infection or Acute Uncomplicated Pyelonephritis
title_full_unstemmed Population Pharmacokinetic Analysis of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Healthy Subjects, Subjects with Various Degrees of Renal Function, and Patients with Complicated Urinary Tract Infection or Acute Uncomplicated Pyelonephritis
title_short Population Pharmacokinetic Analysis of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Healthy Subjects, Subjects with Various Degrees of Renal Function, and Patients with Complicated Urinary Tract Infection or Acute Uncomplicated Pyelonephritis
title_sort population pharmacokinetic analysis of cefiderocol, a parenteral siderophore cephalosporin, in healthy subjects, subjects with various degrees of renal function, and patients with complicated urinary tract infection or acute uncomplicated pyelonephritis
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5786804/
https://www.ncbi.nlm.nih.gov/pubmed/29038272
http://dx.doi.org/10.1128/AAC.01391-17
work_keys_str_mv AT kawaguchinao populationpharmacokineticanalysisofcefiderocolaparenteralsiderophorecephalosporininhealthysubjectssubjectswithvariousdegreesofrenalfunctionandpatientswithcomplicatedurinarytractinfectionoracuteuncomplicatedpyelonephritis
AT katsubetakayuki populationpharmacokineticanalysisofcefiderocolaparenteralsiderophorecephalosporininhealthysubjectssubjectswithvariousdegreesofrenalfunctionandpatientswithcomplicatedurinarytractinfectionoracuteuncomplicatedpyelonephritis
AT echolsroger populationpharmacokineticanalysisofcefiderocolaparenteralsiderophorecephalosporininhealthysubjectssubjectswithvariousdegreesofrenalfunctionandpatientswithcomplicatedurinarytractinfectionoracuteuncomplicatedpyelonephritis
AT wajimatoshihiro populationpharmacokineticanalysisofcefiderocolaparenteralsiderophorecephalosporininhealthysubjectssubjectswithvariousdegreesofrenalfunctionandpatientswithcomplicatedurinarytractinfectionoracuteuncomplicatedpyelonephritis